JDD Buzz | Impact of Weight Loss on Soft Tissue
From news articles to social media, “Ozempic face” is commonly used to describe facial changes that accompany rapid weight loss from GLP-1 receptor agonists. A gaunt, sunken, and aged appearance is commonly attributed to Ozempic and other GLP-1s. However, bariatric surgery and dietary changes can also lead to skin laxity and loss of facial volume. Irrespective of the weight loss method, patien …
From news articles to social media, “Ozempic face” is commonly used to describe facial changes that accompany rapid weight loss from GLP-1 receptor agonists. A gaunt, sunken, and aged appearance is commonly attributed to Ozempic and other GLP-1s. However, bariatric surgery and dietary changes can also lead to skin laxity and loss of facial volume. Irrespective of the weight loss method, patien … Continue reading "JDD Buzz | Impact of Weight Loss on Soft Tissue"
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition.1 Due to its longer duration of action, it is typically administered subcutaneously once weekly. The safety profile of semaglutide is similar to …